Endpoints News 生物医药· Max Gelman·· 2 天前AI 评分48
FDA就ivonescimab拒信提示VEGF相关安全性担忧并称获益较有限
FDA letter rejecting Summit cancer drug cites ‘modest’ benefit in data compared with toxicity risk
AI 导读
FDA在向Summit Therapeutics和Akeso发出的拒信中,对癌症药物ivonescimab的安全性表示关注,并指出其临床获益相比毒性风险为
正文
The FDA signaled new interest in the safety of Summit Therapeutics and Akeso’s cancer drug ivonescimab, saying that it turned down the …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
来源:Endpoints News 生物医药 · endpoints.news